FINNENCE ▪ THE WIRE FILE
THE WIRE · № 72976
Company■ Unclear/unknown
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES5
ENTITIES1
STORY SIZE5 RECORDS
FIRST SEEN2026-10-09 12:00 UTC
LAST UPDATE2026-10-09 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A large Phase 3 asthma study is a pipeline milestone for Pfizer but years from commercialization.
Pipeline news, immaterial to near-term earnings
CATALYST TO WATCH
Topline Phase 3 asthma data
MAIN RISK
Failure in a competitive asthma market
FULL DISPATCH
Sponsor: Pfizer; Status: Recruiting; Conditions: Asthma; Interventions: tilrekimig, Placebo; Enrollment: 1100 (estimated); First posted: 2026-10-09; NCT: NCT07869043
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 5 TIMES · FIRST 2026-10-09 12:00 UTC · LAST 2026-10-09 12:00 UTC2026-10-09 12:00 UTCCompanyNew Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.
2026-10-09 12:00 UTCCompanyNew Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — PfizerCURRENT RECORD
2026-10-09 12:00 UTCCompanyNew Phase 3 trial: A Clinical Trial on the Effect of Infant Formula Consumption on Growth, Immune Parameters, and Gut Health in Healthy Term Infants. — FrieslandCampina
2026-10-09 12:00 UTCCompanyNew Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics
2026-10-09 12:00 UTCCompanyNew Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics2026-10-09 12:00 UTC
New Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics2026-10-09 12:00 UTC
New Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Hoffmann-La Roche2026-10-09 12:00 UTC
Phase 3 results posted: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Hoffmann-La Roche2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
CTY IPO News - RNA interference biotech City Therapeutics sets terms for $175 million IPO2026-10-09 12:44 UTC
CTY IPO News - RNA interference biotech City Therapeutics sets terms for $175 million IPO2026-10-09 12:44 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.